Company intelligence / Profile preview

BMImmune

Coralville, Iowa, United States

Ownership: Private

Overview

BMImmune is a pre-clinical stage biotechnology company focused on developing novel cancer immunotherapies by targeting lipid metabolism pathways. Founded by immunologist Dr. Bing Li, the company leverages research on fatty acid-binding proteins (FABPs), specifically FABP4 (adipose FABP) and FABP5, which link obesity, chronic inflammation, and cancer progression. BMImmune's lead program is a novel humanized monoclonal antibody targeting extracellular A-FABP (FABP4) for the treatment of triple-negative breast cancer (TNBC). By neutralizing circulating FABPs, the company aims to disrupt the metabolic support system of tumors and reduce the risk of obesity-associated cancer progression.

Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on BMImmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMImmune.

Explore the full profile